poractant alfa 80mg/mL (1.5mL, 3mL) suspension

© Department of Health, Government of South Australia. All rights reserved.



Curosurf®



ISBN number: **Endorsed by:** Contact:

poractant alfa

80mg/mL (1.5mL, 3mL) suspension

© Department of Health, Government of South Australia. All rights reserved.

Dose and Indications

Treatment and prevention of respiratory distress syndrome (RDS) in preterm infants

Endotracheal

For infants ≤32 weeks gestation: initial dose 200mg/kg (2.5mL/kg); subsequent dose 100mg/kg (1.25mL) repeated at 12 hourly intervals if required. Dose is rounded to the nearest vial to avoid wastage.

For infants >32 weeks gestation: 100mg/kg/dose (1.25mL/kg) for first and subsequent doses. Dose is rounded to the nearest vial to avoid wastage.

Meconium Aspiration Pneumonitis

Endotracheal

100mg/kg (1.25mL/kg) only on consultant's recommendation

Preparation and Administration

Endotracheal

Administer via an endotracheal tube. Follow appropriate Neonatal Unit specific procedures and guidelines.

- > Store in the refrigerator, but warm to room temperature before use
- > Invert vial gently without shaking to re-suspend the material
- > Any remaining in vial should be discarded.

Compatible Fluids

Do not dilute with any fluid

Adverse Effects

Common

Transient endotracheal tube obstruction, transient bradycardia and decreased oxygen saturation



ISBN number: Endorsed by: Contact: 978-1-74243-426-1 South Australian Maternal & Neonatal Clinical Network South Australian Neonatal Medication Guidelines Workgroup at: NeoMed@health.sa.gov.au Page **2** of **4**

poractant alfa 80mg/mL (1.5mL, 3mL) suspension

© Department of Health, Government of South Australia. All rights reserved.

Infrequent

Hypotension

Rare

Pulmonary haemorrhage (particularly in very premature infants)

Practice Points

- Surfactants can be used to treat established RDS (rescue treatment) or as preventive treatment, administered shortly after birth to infants considered to be at significant risk of developing RDS
- Preventive or rescue treatment with surfactant reduces mortality and morbidity of preterm infants (<32 weeks gestation) with RDS; preventive treatment is more effective than rescue treatment
- > Use with care when using high frequency ventilation because of the risk of airway obstruction
- Pulmonary surfactants are also used to treat meconium aspiration syndrome although evidence is limited
- > Unopened vials that have been warmed to room temperature at one time may be returned to the refrigerator within 24 hours. Vials should not be warmed and returned to the refrigerator more than once.

Reference

Ramananthan R, Rasmussen M, Gerstmann D, Finer N, Sekar K and The North American Study Group. A Randomized, Multicenter Masked Comparison Trial of Poractant Alfa (Curosurf) verses Beractant (Survanta) in the Treatment of Respiratory Distress Syndrome in Preterm Infants. American Journal of Perinatology 2004; 21 (3): 109-119



poractant alfa

80mg/mL (1.5mL, 3mL) suspension

© Department of Health, Government of South Australia. All rights reserved.

Version control and change history

PDS reference: OCE use only

| Date from | Date to | Amendment | |
|---------------|---------|------------------|--|
| November 2012 | current | Original version | |
| | | | |
| | | | |
| | | | |
| | | | |



ISBN number: Endorsed by: Contact:

978-1-74243-426-1 South Australian Maternal & Neonatal Clinical Network South Australian Neonatal Medication Guidelines Workgroup at: NeoMed@health.sa.gov.au